October 2021 OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting
October 2021 OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo®
October 2021 OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of CoVepiT
October 2021 OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with BI 765063
October 2021 OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance
October 2021 OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement for FR 104
October 2021 OSE Immunotherapeutics Announces First Peer-Reviewed Publication in Science Advances on OSE-230